Monopar Therapeutics MNPR Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's total liabilities?
- Monopar Therapeutics (MNPR) reported total liabilities of $2.59M in Q1 2026.
- How has Monopar Therapeutics's total liabilities changed year-over-year?
- Monopar Therapeutics's total liabilities increased by 73.6% year-over-year, from $1.49M to $2.59M.
- What is the long-term trend for Monopar Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total liabilities has grown at a 19.7% compound annual growth rate (CAGR), from $1.18M to $2.89M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.